|
Importance of hard 3-point MACE endpoints
|
5
|
Resverlogix Corp.
|
Mar 19, 2018 03:32PM
|
|
Stonegate Capital Partners Research Report 3/19/2018
|
3
|
Resverlogix Corp.
|
Mar 19, 2018 04:51PM
|
|
Re: Stonegate Capital Partners Research Report 3/19/2018
|
5
|
Resverlogix Corp.
|
Mar 19, 2018 06:39PM
|
|
Re: Delivery peptide conjugates of Trastuzumab
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 20, 2018 10:24AM
|
|
Re: Delivery peptide conjugates of Trastuzumab
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 20, 2018 02:28PM
|
|
Re: Delivery peptide conjugates of Trastuzumab
|
2
|
BIOASIS TECHNOLOGIES INC
|
Mar 20, 2018 03:40PM
|
|
Re: time to add/3 vs 5 pt. MACE
|
10
|
Resverlogix Corp.
|
Mar 20, 2018 11:23PM
|
|
Re: Delivery peptide conjugates of Trastuzumab
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 20, 2018 11:33PM
|
|
Re: Dr. Deborah Rathjen, CEO & Managing Director of Bionomics Appointed Chair of the Bioasis Board of Directors
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 21, 2018 09:44AM
|
|
Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors
|
|
BIOASIS TECHNOLOGIES INC
|
Mar 21, 2018 09:49AM
|
|
The BET inhibitor mCRPC papers keep piling up
|
4
|
Zenith Epigenetics
|
Mar 21, 2018 11:33AM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 21, 2018 11:36AM
|
|
Re: BIO-Europe Presentation
|
5
|
Zenith Epigenetics
|
Mar 21, 2018 11:37AM
|
|
Re: time to add/3 vs 5 pt. MACE
|
6
|
Resverlogix Corp.
|
Mar 21, 2018 11:47AM
|
|
Re: time to add/3 vs 5 pt. MACE
|
3
|
Resverlogix Corp.
|
Mar 21, 2018 12:42PM
|
|
Re: time to add/3 vs 5 pt. MACE
|
5
|
Resverlogix Corp.
|
Mar 21, 2018 03:14PM
|
|
Re: time to add/3 vs 5 pt. MACE
|
2
|
Resverlogix Corp.
|
Mar 22, 2018 01:46AM
|
|
AEGIS-II trial
|
2
|
Resverlogix Corp.
|
Mar 22, 2018 10:09AM
|
|
Re: AEGIS-II trial
|
2
|
Resverlogix Corp.
|
Mar 22, 2018 01:06PM
|
|
Re: AEGIS-II trial
|
2
|
Resverlogix Corp.
|
Mar 22, 2018 01:29PM
|
